Table 2 Complete data of 10 patients.

From: Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease

Pat

Age

Gender

Type

DS stage

ISS stage

RISS stage

ECOG score

FISH

Extramedullary involvement

Response

AEs

PFS

 

1

58

Female

IgDλ

IIIA

III

III

2

1q21+

Kidney

VGPR

Nausea/Anorexia/ Myelosuppression

4

 

2

61

Male

IgGκ

IIIA

III

II

1

Normal

Rib

VGPR

Nausea/Vomiting/Fatigue

18

 

3

66

Male

IgGκ

IIIA

II

II

0

Normal

Thoracic

sCR

Fever/ Myelosuppression

18

 

4

59

Male

κ

IIIA

II

II

0

Normal

Thoracic

CR

Fatigue

16

 

5

55

Female

IgGλ

IIIA

II

II

0

1q21+/13q-

Humerus/femur

sCR

Fatigue/Myelosuppression

15

 

6

56

Male

IgAκ

IIIA

I

I

1

Normal

Nasal cavity

VGPR

Nausea/Anorexia

7

 

7

69

Female

IgGκ

IIIA

II

II

2

Normal

CNS

PR

Fatigue

6

 

8

68

Female

IgGλ

IIIA

II

II

2

Normal

Lung

CR

Celialgia/Myelosuppression

18

 

9

81

Female

κ

IIIA

III

III

1

17p-/1q21+

Eye

PR

Thrombocytopenia

9

 

10

63

Male

λ

IIA

II

II

1

Normal

Ilium

VGPR

Myelosuppression

15

 
  1. Pat—Patient; DS—The Multiple Myeloma Durie-Salmon Staging System; ISS—The Multiple Myeloma International Staging System; RISS—Revised International Staging System; VGPR—very good partial response; PR—partial response; ECOG—Eastern Cooperative Oncology Group; FISH—Fluorescence In Situ Hybridization; CNS—central nervous system; AEs—Adverse Events.